NCT03695146

Brief Summary

The aim of the study is to investigate the neural underpinnings of cardiovascular reactivity to mental stress as a function of HIV and hypertensive risk.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started Aug 2019

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 28, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 3, 2018

Completed
11 months until next milestone

Study Start

First participant enrolled

August 19, 2019

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2023

Completed
Last Updated

February 15, 2024

Status Verified

February 1, 2024

Enrollment Period

4.3 years

First QC Date

September 28, 2018

Last Update Submit

February 14, 2024

Conditions

Keywords

High blood pressureHIV

Outcome Measures

Primary Outcomes (1)

  • Change in heart rate variability

    Heart rate variability will be measured using a standard electrocardiogram to detect variability in R -to-R intervals.

    Baseline, pre-intervention and up to 60 minutes post-intervention

Secondary Outcomes (1)

  • Change in cytokine expression in peripheral blood mononuclear cells

    Baseline, pre-intervention and up to 60 minutes post-intervention

Study Arms (3)

Paced breathing

EXPERIMENTAL

Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.

Behavioral: Paced breathing

Relaxing music

ACTIVE COMPARATOR

Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.

Behavioral: Active relaxation

No intervention

NO INTERVENTION

Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.

Interventions

Paced breathingBEHAVIORAL

Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.

Paced breathing

Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.

Relaxing music

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • pre-hypertension screening.
  • HIV-antibody testing.

You may not qualify if:

  • current use of anti-lipid, antihypertensive, or heart rate altering medications;
  • current or lifetime history of cardiovascular disease diagnosis or treatment including pulmonary stenosis, heart valve abnormalities and hypertension;
  • current or lifetime diagnoses of cancer, kidney/liver disease, hypertension, Type 1 or Type 2 diabetes;
  • history of trauma, cerebral infarction or hemorrhage;
  • current diagnosis and/or treatment for hypertension;
  • severe cognitive impairment;
  • current treatment or diagnosis of psychiatric illness;
  • metal implants or debris within the body; or pregnancy;
  • body mass index \> 35;
  • use of hormone replacement therapy; and current smoker.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami

Miami, Florida, 33136, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Roger C McIntosh, Ph.D.

    University of Miami, College of Arts and Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

September 28, 2018

First Posted

October 3, 2018

Study Start

August 19, 2019

Primary Completion

December 1, 2023

Study Completion

December 22, 2023

Last Updated

February 15, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations